WA
PRTK

Waverly Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Waverly Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,670
Closed -$83K – 411
2015
Q1 		$83K Hold
2,670
– – 0.04% 84
2014
Q4 		$103K Buy
+2,670
New +$63.8K 0.05% 74
2014
Q3 		– Sell
-223
Closed -$5K – 794
2014
Q2 		$5K Hold
223
– – ﹤0.01% 598
2014
Q1 		$8K Hold
223
– – ﹤0.01% 478
2013
Q4 		$9K Buy
+223
New +$9.47K ﹤0.01% 575

Other funds holding PRTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Waverly Advisors's PRTK Position: Q2 2015 in Review

Waverly Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2015, closing a stake of 2,670 shares — an estimated $83K sold.

Waverly Advisors first reported a position in PRTK in Q4 2013 and held it in 5 quarters. The position peaked at $103K in Q4 2014. 68 funds tracked by Wall St. Rank hold PRTK as of Q2 2015.

  • Waverly Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Waverly Advisors sold 2,670 Paratek Pharmaceuticals, Inc. shares in Q2 2015, an estimated $83K.
  • Waverly Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2013 and held it in 5 quarters.
  • Waverly Advisors's Paratek Pharmaceuticals, Inc. position peaked at $103K in Q4 2014.
  • 68 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2015.

Based on Waverly Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.